Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karola Rittner

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Oncoimmunology|July 9, 2015
Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligandXavier Préville, Karola Rittner, Laetitia Fend
The Journal of Gene Medicine|September 2, 2003
Ligation of exogenous linear DNA after gene transfer in vitro and in vivoKarola Rittner, Annie Benavente, Eric Jacobs
Bioinformatics (Oxford, England)|June 7, 2021
BERTMHC: improved MHC-peptide class II interaction prediction with transformer and multiple instance learningJun Cheng, Kaïdre Bendjama, Karola Rittner, et al.
Oncotarget|February 22, 2018
NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon responseAnne Oberson, Lorenzo Spagnuolo, Viola Puddinu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 7, 2002
New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivoKarola Rittner, Annie Benavente, Albine Bompard-Sorlet, et al.
Cancer Immunology Research|August 30, 2014
Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonistLaetitia Fend, Tanja Gatard-Scheikl, Jacqueline Kintz, et al.
Oncoimmunology|December 18, 2012
TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapyLaurent Amiset, Laetitia Fend, Tania Gatard-Scheikl, et al.
Vaccine|December 26, 2016
Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumorsEmmanuelle Schaedler, Christelle Remy-Ziller, Julie Hortelano, et al.
Human Vaccines & Immunotherapeutics|September 20, 2017
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor modelChristelle Remy-Ziller, Christine Thioudellet, Julie Hortelano, et al.
Journal of Extracellular Vesicles|June 19, 2026
Therapeutic Poxviruses Induce the Secretion of Immunostimulating and Anti-Tumoral Extracellular VesiclesLucas Walther, Vincent Mittelheisser, Marie-Christine Claudepierre, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Oncoimmunology|July 9, 2015
Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligandXavier Préville, Karola Rittner, Laetitia Fend
The Journal of Gene Medicine|September 2, 2003
Ligation of exogenous linear DNA after gene transfer in vitro and in vivoKarola Rittner, Annie Benavente, Eric Jacobs
Bioinformatics (Oxford, England)|June 7, 2021
BERTMHC: improved MHC-peptide class II interaction prediction with transformer and multiple instance learningJun Cheng, Kaïdre Bendjama, Karola Rittner, et al.
Oncotarget|February 22, 2018
NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon responseAnne Oberson, Lorenzo Spagnuolo, Viola Puddinu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 7, 2002
New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivoKarola Rittner, Annie Benavente, Albine Bompard-Sorlet, et al.
Cancer Immunology Research|August 30, 2014
Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonistLaetitia Fend, Tanja Gatard-Scheikl, Jacqueline Kintz, et al.
Oncoimmunology|December 18, 2012
TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapyLaurent Amiset, Laetitia Fend, Tania Gatard-Scheikl, et al.
Vaccine|December 26, 2016
Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumorsEmmanuelle Schaedler, Christelle Remy-Ziller, Julie Hortelano, et al.
Human Vaccines & Immunotherapeutics|September 20, 2017
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor modelChristelle Remy-Ziller, Christine Thioudellet, Julie Hortelano, et al.
Journal of Extracellular Vesicles|June 19, 2026
Therapeutic Poxviruses Induce the Secretion of Immunostimulating and Anti-Tumoral Extracellular VesiclesLucas Walther, Vincent Mittelheisser, Marie-Christine Claudepierre, et al.
Pageof 2